Department of Hygiene and Epidemiology, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
Division of Infectious Diseases, Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, United States of America.
PLoS One. 2020 Oct 23;15(10):e0240654. doi: 10.1371/journal.pone.0240654. eCollection 2020.
Almost 13 million people are estimated to be on antiretroviral therapy in Eastern and Southern Africa, and their disease course and program effectiveness could be significantly affected by the concurrent use of alcohol. Screening for alcohol use may be important to assess the prevalence of alcohol consumption and its impact on patient and programmatic outcomes.
As part of this observational study, data on patient characteristics and alcohol consumption were collected on a cohort of 765 adult patients enrolling in HIV care in East Africa. Alcohol consumption was assessed with the AUDIT questionnaire at enrollment. Subjects were classified as consuming any alcohol (AUDIT score >0), hazardous drinkers (AUDIT score ≥8) and hyper drinkers (AUDIT score ≥16). The effects of alcohol consumption on retention in care, death and delays in antiretroviral therapy (ART) initiation were assessed through competing risk (Fine & Gray) models.
Of all study participants, 41.6% consumed alcohol, 26.7% were classified as hazardous drinkers, and 16.0% as hyper drinkers. Depending on alcohol consumption classification, men were 3-4 times more likely to consume alcohol compared to women. Hazardous drinkers (median age 32.8 years) and hyper drinkers (32.7 years) were slightly older compared to non-hazardous drinkers (30.7 years) and non-hyper drinkers (30.8 years), (p-values = 0.014 and 0.053 respectively). Median CD4 at enrollment was 330 cells/μl and 16% were classified World Health Organization (WHO) stage 3 or 4. There was no association between alcohol consumption and CD4 count or WHO stage at enrollment. Alcohol consumption was associated with significantly lower probability of ART initiation (adjusted sub-distribution hazard ratio aSHR = 0.77 between alcohol consumers versus non-consumers; p-value = 0.008), and higher patient non-retention in care (aSHR = 1.77, p-value = 0.023).
Alcohol consumption is associated with significant delays in ART initiation and reduced retention in care for patients enrolling in HIV care and treatment programs in East Africa. Consequently, interventions that target alcohol consumption may have a significant impact on the HIV care cascade.
据估计,在东非和南非,有近 1300 万人正在接受抗逆转录病毒治疗,他们的疾病进程和项目效果可能会受到同时使用酒精的显著影响。筛查饮酒情况可能对评估酒精消费的流行程度及其对患者和项目结果的影响很重要。
作为这项观察性研究的一部分,在东非艾滋病毒护理中登记的 765 名成年患者的队列中收集了患者特征和酒精消费数据。在入组时使用 AUDIT 问卷评估酒精消费。将饮酒者分为有任何饮酒行为者(AUDIT 评分>0)、危险饮酒者(AUDIT 评分≥8)和过度饮酒者(AUDIT 评分≥16)。通过竞争风险(Fine 和 Gray)模型评估饮酒对保留护理、死亡和延迟开始抗逆转录病毒治疗(ART)的影响。
在所有研究参与者中,41.6%的人饮酒,26.7%的人被归类为危险饮酒者,16.0%的人被归类为过度饮酒者。根据饮酒分类,男性饮酒的可能性是女性的 3-4 倍。与非危险饮酒者(30.7 岁)和非过度饮酒者(30.8 岁)相比,危险饮酒者(中位年龄 32.8 岁)和过度饮酒者(32.7 岁)年龄稍大(p 值分别为 0.014 和 0.053)。入组时的中位 CD4 为 330 个细胞/μl,16%的人被归类为世界卫生组织(WHO)第 3 或 4 期。饮酒与入组时的 CD4 计数或 WHO 分期无相关性。饮酒与开始接受 ART 的可能性显著降低(饮酒者与非饮酒者之间的调整亚分布风险比 aSHR = 0.77;p 值=0.008)和患者保留护理率降低显著相关(aSHR = 1.77,p 值=0.023)。
在东非艾滋病毒护理和治疗项目中,饮酒与开始接受 ART 的显著延迟和保留护理率降低有关。因此,针对酒精消费的干预措施可能会对艾滋病毒护理链产生重大影响。